Cargando…
Interrogation of the Structure–Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications
PR-104A is a dual hypoxia/nitroreductase gene therapy prodrug by virtue of its ability to undergo either one- or two-electron reduction to its cytotoxic species. It has been evaluated extensively in pre-clinical GDEPT studies, yet off-target human aldo-keto reductase AKR1C3-mediated activation has l...
Autores principales: | Ashoorzadeh, Amir, Mowday, Alexandra M., Guise, Christopher P., Silva, Shevan, Bull, Matthew R., Abbattista, Maria R., Copp, Janine N., Williams, Elsie M., Ackerley, David F., Patterson, Adam V., Smaill, Jeff B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877822/ https://www.ncbi.nlm.nih.gov/pubmed/35215297 http://dx.doi.org/10.3390/ph15020185 |
Ejemplares similares
-
Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3
por: Abbattista, Maria R., et al.
Publicado: (2021) -
Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
por: Guise, Christopher P., et al.
Publicado: (2014) -
E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications
por: Mowday, Alexandra Marie, et al.
Publicado: (2020) -
The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy
por: Green, Laura K., et al.
Publicado: (2013) -
Pseudomonas aeruginosa NfsB and nitro-CBI-DEI – a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy
por: Green, Laura K, et al.
Publicado: (2013)